Genitourinary Cancer
Conference Coverage
Abiraterone also benefits low-risk metastatic prostate cancer patients
MUNICH – Analyses of STAMPEDE trial data using risk criteria from two other trials revealed distinct survival benefits with abiraterone, ADT, and...
Conference Coverage
STAMPEDE: Radiation to prostate boosts survival of metastatic cancer
MUNICH – Patients with low-burden metastatic prostate cancer had an 8% 3-year survival benefit when they received radiation plus androgen...
Conference Coverage
Checkpoint inhibitor/TKI combo improves PFS of RCC over sunitinib
MUNICH – Avelumab and axitinib offered better progression-free survival than did sunitinib as first-line therapy for advanced renal cell carcinoma...
News
No ADT-dementia link in large VA prostate cancer cohort study
No significant association was found between use of ADT and development of any dementia in an observational cohort study of more than 45,000...
News
CT features associated with (some) ccRCC subtypes
Radiogenomic analysis showed that well-defined tumor margins and other features were associated with specific clinical presentations.
Audio
ACS: Screen for colon cancer at 45
And testosterone therapy may impact kidney stone risk.
News
World Trade Center responders face greater cancer burden, including greater risk of multiple myeloma
The prevalence of multiple myeloma precursor disease was more than threefold higher in WTC exposed firefighters.